Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference
22 févr. 2024 08h30 HE
|
Cerevance
BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced participation at the...
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters
15 févr. 2024 08h30 HE
|
Cerevance
BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing...
Cerevance to Participate in Fireside Chat at the 2023 RBC Capital Markets Healthcare Private Company Virtual Conference
05 déc. 2023 08h30 HE
|
Cerevance
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced that chief executive...
Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
28 nov. 2023 08h30 HE
|
Cerevance
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced a poster presentation at...
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
13 nov. 2023 08h30 HE
|
Cerevance
Study to assess efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease BOSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel...
Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting
07 nov. 2023 09h09 HE
|
Cerevance
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster...
Cerevance to Participate in the Truist Securities BioPharma Symposium
01 nov. 2023 08h00 HE
|
Cerevance
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development developing precision novel therapeutics for central nervous system (CNS) diseases using...
Cerevance to Participate at the Wells Fargo 2023 Private Biotech Symposium
25 oct. 2023 08h00 HE
|
Cerevance
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...
Cerevance to Participate at the Leerink Biopharma Private Company Connect
18 oct. 2023 08h00 HE
|
Cerevance
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...
Cerevance to Participate at the 3rd Annual Needham Biotech Private Company Forum
10 oct. 2023 08h00 HE
|
Cerevance
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...